These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies. Wang J; Garancher A; Ramaswamy V; Wechsler-Reya RJ Annu Rev Neurosci; 2018 Jul; 41():207-232. PubMed ID: 29641939 [TBL] [Abstract][Full Text] [Related]
5. Medulloblastoma: From Myth to Molecular. Ramaswamy V; Taylor MD J Clin Oncol; 2017 Jul; 35(21):2355-2363. PubMed ID: 28640708 [TBL] [Abstract][Full Text] [Related]
6. The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined Therapies. Slika H; Alimonti P; Raj D; Caraway C; Alomari S; Jackson EM; Tyler B Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568705 [TBL] [Abstract][Full Text] [Related]
7. Current medulloblastoma subgroup specific clinical trials. Thompson EM; Ashley D; Landi D Transl Pediatr; 2020 Apr; 9(2):157-162. PubMed ID: 32477916 [TBL] [Abstract][Full Text] [Related]
8. Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes. Korshunov A; Okonechnikov K; Schrimpf D; Tonn S; Mynarek M; Koster J; Sievers P; Milde T; Sahm F; Jones DTW; von Deimling A; Pfister SM; Kool M Acta Neuropathol; 2023 Jun; 145(6):829-842. PubMed ID: 37093271 [TBL] [Abstract][Full Text] [Related]
10. Medulloblastoma: Molecular understanding, treatment evolution, and new developments. Liu X; Ding C; Tan W; Zhang A Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673 [TBL] [Abstract][Full Text] [Related]
11. The Alliance AMBUSH Trial: Rationale and Design. Mahajan A; Shih H; Penas-Prado M; Ligon K; Aldape K; Hu LS; Loughan AR; Basso MR; Leeper HE; Nahed BV; Stott SL; Geyer S; Giannini C; Galanis E Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053576 [TBL] [Abstract][Full Text] [Related]
12. Medulloblastoma targeted therapy: From signaling pathways heterogeneity and current treatment dilemma to the recent advances in development of therapeutic strategies. Wang Q; Xin X; Dai Q; Sun M; Chen J; Mostafavi E; Shen Y; Li X Pharmacol Ther; 2023 Oct; 250():108527. PubMed ID: 37703952 [TBL] [Abstract][Full Text] [Related]
13. Medulloblastoma in China: clinicopathologic analyses of SHH, WNT, and non-SHH/WNT molecular subgroups reveal different therapeutic responses to adjuvant chemotherapy. Zhang ZY; Xu J; Ren Y; Li KK; Ng HK; Mao Y; Zhong P; Yao Y; Zhou LF PLoS One; 2014; 9(6):e99490. PubMed ID: 24932704 [TBL] [Abstract][Full Text] [Related]
14. Identification of Let-7 miRNA Activity as a Prognostic Biomarker of SHH Medulloblastoma. Westphal MS; Lee E; Schadt EE; Sholler GS; Zhu J Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008302 [TBL] [Abstract][Full Text] [Related]
15. Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions. Alharbi M; Mobark N; Bashawri Y; Abu Safieh L; Alowayn A; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; AlSolme E; Ahmad M; Al-Banyan A; Alotabi FE; Serrano J; Snuderl M; Al-Rashed M; Abedalthagafi M Front Neurol; 2020; 11():167. PubMed ID: 32265819 [TBL] [Abstract][Full Text] [Related]